Our results showing the efficacy of Merestinib18,36 in suppressing not only MAPK-eIF4E signals but also CDK1 and the oncofetal RNA binding protein, IMP3, which is induced by MAPK signals and overexpressed linked to many types of aggressive tumors37 are highly significant toward developing IBC-specific therapeutic strategies. Here, CDK1 is linked to inflammatory breast carcinoma.